Kyle T Wright
Overview
Explore the profile of Kyle T Wright including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paczkowska J, Tang M, Wright K, Song L, Luu K, Shanmugam V, et al.
Nat Commun
. 2024 Dec;
15(1):10740.
PMID: 39737927
Hodgkin Reed-Sternberg (HRS) cells of classic Hodgkin lymphoma (cHL), like many solid tumors, elicit ineffective immune responses. However, patients with cHL are highly responsive to PD-1 blockade, which largely depends...
2.
Wright K, Weirather J, Jiang S, Kao K, Sigal Y, Giobbie-Hurder A, et al.
Blood Adv
. 2023 May;
7(16):4633-4646.
PMID: 37196647
Diffuse large B-cell lymphoma (DLBCL) not otherwise specified is the most common aggressive non-Hodgkin lymphoma and a biologically heterogeneous disease. Despite the development of effective immunotherapies, the organization of the...
3.
Lee P, Klaeger S, Le P, Korthauer K, Cheng J, Ananthapadmanabhan V, et al.
J Clin Invest
. 2022 Jul;
132(13).
PMID: 35775490
Cancers avoid immune surveillance through an array of mechanisms, including perturbation of HLA class I antigen presentation. Merkel cell carcinoma (MCC) is an aggressive, HLA-I-low, neuroendocrine carcinoma of the skin...
4.
Ng J, Guo F, Marneth A, Ghanta S, Kwon M, Keegan J, et al.
Blood Adv
. 2020 Oct;
4(19):4965-4979.
PMID: 33049055
Patients with immune deficiencies from cancers and associated treatments represent a growing population within the intensive care unit with increased risk of morbidity and mortality from sepsis. Mesenchymal stromal cells...
5.
Anderson J, Ho V, Wright K, Levy B, Loscalzo J
N Engl J Med
. 2020 Sep;
383(14):1376-1381.
PMID: 32997914
No abstract available.
6.
Adler A, Mittal P, Hagymasi A, Menoret A, Shen C, Agliano F, et al.
Oncogene
. 2020 Jan;
39(11):2424-2436.
PMID: 31959897
Metastatic tumors that have become resistant to androgen deprivation therapy represent the major challenge in treating prostate cancer. Although these recurrent tumors typically remain dependent on the androgen receptor (AR),...
7.
8.
Merryman R, Armand P, Wright K, Rodig S
Blood Adv
. 2018 Jan;
1(26):2643-2654.
PMID: 29296917
Classical Hodgkin lymphoma (cHL) is characterized by nearly universal genetic alterations in 9p24.1, resulting in constitutive expression of PD-1 ligands. This likely underlies the unique sensitivity of cHL to PD-1...
9.
Wright K, Giardina C, Vella A
Biochem Pharmacol
. 2014 Sep;
92(2):184-91.
PMID: 25204592
Inflammatory responses can vary depending on a myriad of factors including: (1) the initiating stimulus or trigger, (2) the cell types involved in the response, and (3) the specific effector...
10.
Clark R, Cervantes J, Maciejewski M, Farrokhi V, Nemati R, Yao X, et al.
Infect Immun
. 2013 Jul;
81(9):3479-89.
PMID: 23836823
The total cellular lipids of Porphyromas gingivalis, a known periodontal pathogen, were previously shown to promote dendritic cell activation and inhibition of osteoblasts through engagement of Toll-like receptor 2 (TLR2)....